Protective effect opf lodoxamide tromethamine on allergen inhalation challenge.
Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.
D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000627:therapeutic use*; D000704:Analysis of Variance; D001249:Asthma / Q000175:diagnosis / Q000517:prevention & control*; D001985:Bronchial Provocation Tests; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D009570:Nitriles; D010072:Oxamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010919:Placebos; D013997:Time Factors; D014325:Tromethamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000596:Amino Acids; D009570:Nitriles; D010919:Placebos; D014325:Tromethamine; C022028:lodoxamide tromethamine; D010072:Oxamic Acid